检测淋巴瘤患者的循环肿瘤 DNA。

Detection of Circulating Tumor DNA in Lymphoma Patients.

机构信息

Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.

Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

出版信息

Methods Mol Biol. 2025;2865:475-490. doi: 10.1007/978-1-0716-4188-0_21.

DOI:10.1007/978-1-0716-4188-0_21

PMID:39424738

Abstract

Liquid biopsy has become an opportunity in lymphoma diagnostics, since plasma circulating tumor DNA (ctDNA) is an easily accessible source of tumor DNA, which can be complementary to tissue biopsy. Through ctDNA, lymphomas can be molecularly characterized, tumor clonal evolution can be tracked, while monitoring minimal residual diseases during and after therapy. Here, we describe the methodology of cancer personalized profiling by deep sequencing (CAPP-seq) that we use for ctDNA qualification and quantification.

摘要

液体活检在淋巴瘤诊断中已成为一种机遇，因为血浆中循环肿瘤 DNA（ctDNA）是肿瘤 DNA 的一种易于获取的来源，它可以作为组织活检的补充。通过 ctDNA，淋巴瘤可以进行分子特征分析，肿瘤克隆进化可以被追踪，同时在治疗期间和之后监测微小残留病灶。在这里，我们描述了我们用于 ctDNA 定性和定量的癌症个体化深度测序分析（CAPP-seq）的方法学。